Dexcom Takeaways From the 2026 Analyst Day

Research evidence excerpt

Dexcom Takeaways From the 2026 Analyst Day

J P M O R G A N North America Equity Research

15 May 2026

Dexcom Neutral

DXCM, DXCM US

Takeaways From the 2026 Analyst Day Price (14 May 26):$57.82

Medical Supplies & Devices

Dexcom hosted its 2026 Investor Day yesterday in Tempe, and the message Robbie Marcus, CFA AC

centered on tightening execution, formalizing a longer-dated durable double- (1-212) 464-5599

digit revenue growth, an above-industry margin expansion algorithm, and re- robert.j.marcus@jpmorgan.com

anchoring the next major catalyst around Type 2 NIT clinical evidence and Allen Gong

eventual Medicare coverage. Key takeaways were: (1) governance (1-212) 622-9520

enhancements following constructive engagement with Elliott after they disclosed allen.gong@jpmorgan.com

a large stake (two new independent directors and expanded oversight via a Lilia-Celine B Lozada

reconstituted Operations and Innovation Committee across operations, quality, (1-212) 622-1019

lilia-celine.b.lozada@jpmchase.com

and the technical roadmap); (2) a long-range plan through 2030 calling for 10%+

Henry Householter

revenue growth each year (not a CAGR) alongside a clearer profitability/FCF henry.householter@jpmorgan.com

framework (67–69% gross margin and 29–30% operating margin exiting 2030); J.P. Morgan Securities LLC

(3) the Type 2 NIT RCT readout at ADA 2026 positioned as the evidence anchor

to expand reimbursement in the US and OUS, with Medicare Type 2 NIT still

framed as a potential TAM “doubler” as reimbursement economics inflect around

mid-2027; (4) product cadence anchored on G7 15-day conversion (~50% US base

by YE26; OUS launch 2H26) and G8 (late 2027/early 2028); and (5) a more

explicit capital allocation model (new $1B repurchase authorization in 2026 and